Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 87c
November 4, 2021 5:05 PM EDTVir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of ($0.85), $0.87 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $103.6 million versus the consensus estimate of $138.25 million.
As of September 30, 2021, excluding restricted cash, the Company had approximately $939.5 million in cash, cash equivalents... More
